Pipeline
ITB-MED’s portfolio has projects in several focus areas and in various phases from discovery through clinical development. Our project portfolio as of May 28, 2024.
Transplantation
Kidney
Tolerance
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Tolerance
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Tolerance
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Delayed Tolerance
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Dual co-stimulation blockade
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Induction
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Xenotransplantation
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Liver
Tolerance (non-autoimmune)
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Induction (autoimmune)
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Bone Marrow
GVHD prevention
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Autoimmunity
Type-1 Diabetes
New-onset remission
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
New-onset remission
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
Amyotrophic Lateral Sclerosis
| Phase of trial | |||
|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal |
| AA Focus | Indication | Phase of trial | |||||
|---|---|---|---|---|---|---|---|
| IND-Enabling | Phase 1 | Phase 2 | Pivotal | Trial/Partner | |||
Transplantation | Kidney Kidney Kidney Kidney Kidney Kidney Kidney Kidney Liver Liver Liver Bone Marrow Bone Marrow | Tolerance Tolerance Tolerance Delayed Tolerance Dual co-stimulation blockade Induction Xenotransplantation Tolerance (non-autoimmune) Induction (autoimmune) GVHD prevention | company logos company logos company logos company logos company logos company logos company logos company logos company logos company logos | ||||
Autoimmunity | Type-1 Diabetes Type-1 Diabetes Type-1 Diabetes Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis | New-onset remission New-onset remission | company logos company logos company logos | ||||